Abstract: The invention provides novel iron(III) complexes with formulae (1) and (2). Furthermore, corresponding ligands with formulae (L1) and (L2) for the production of iron(III) complexes are disclosed.

Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).

Abstract: The invention provides novel iron(III) complexes with formulae (1) and (2). Furthermore, corresponding ligands with formulae (L1) and (L2) for the production of iron(III) complexes are disclosed.

Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).

Abstract: The present invention relates to a phosphate adsorbent on the basis of maghemite or maghemite/magnetite comprising (i) an iron oxide core comprising a crystal structure of inverse spinel iron oxide, (ii) a coating selected from monomeric carbohydrates, in particular monosaccharides or disaccharides, alditols, or mixtures thereof, and/or (iii) a pharmaceutical excipient selected from polymeric carbohydrates, wherein the phosphate adsorbent has the form of nanoparticles with a particle size of the iron oxide core (i) of less than 20 nm. The present invention further relates to a method for the production of a phosphate adsorbent on the basis of maghemite or maghemite/magnetite, to pharmaceutical compositions comprising the phosphate adsorbent, and to medical uses thereof, especially for the prevention and/or treatment of hyperphosphatemia.

Abstract: The present invention relates to a phosphate adsorbent on the basis of maghemite or maghemite/magnetite comprising (i) an iron oxide core comprising a crystal structure of inverse spinel iron oxide, (ii) a coating selected from monomeric carbohydrates, in particular monosaccharides or disaccharides, alditols, or mixtures thereof, and/or (iii) a pharmaceutical excipient selected from polymeric carbohydrates, wherein the phosphate adsorbent has the form of nanoparticles with a particle size of the iron oxide core (i) of less than 20 nm. The present invention further relates to a method for the production of a phosphate adsorbent on the basis of maghemite or maghemite/magnetite, to pharmaceutical compositions comprising the phosphate adsorbent, and to medical uses thereof, especially for the prevention and/or treatment of hyperphosphatemia.

Abstract: The present invention relates to the production of marker particles, which are especially useful for target-specific molecular magnetic resonance imaging (MRI), using charged iron oxide nanoparticles and inversely charged peptides covalently linked to macromolecules, which are capable of binding to a specific type of cells.

Abstract: The invention relates to conjugates and methods for in vivo imaging of apoptosis using conjugates of fluorochromes and moieties that bind specifically to apoptotic cells. In specific embodiments, the fluorochrome emits fluorescence in the near-infrared range and is conjugated to a moiety, e.g., a protein such as annexin A5 or synaptotagmin, that binds specifically to apoptotic cells. The methods are non-invasive can be used to obtain images of apoptotic cells in the tissues of living animals, e.g., mammals such as humans.